More specifically, Lin et al. reported that expression of wild-type p53 but not mutant p53 significantly reduces tyrosine phosphorylation of STAT3 and inhibits STAT3 DNA binding in DU145 prostate cancer cell line (47). The gene discussed is TP53; the disease is prostate carcinoma.